Latest news with #Management
Yahoo
4 hours ago
- Business
- Yahoo
5 Insightful Analyst Questions From MarineMax's Q1 Earnings Call
MarineMax delivered a positive Q1, with results surpassing Wall Street's revenue and profit expectations and a strong market reaction following the announcement. Management attributed the quarter's outperformance to aggressive pricing, targeted promotions, and increased digital marketing, which helped drive double-digit same-store sales growth. CEO Brett McGill emphasized the company's ability to leverage technology and analytics, stating, 'Our digital investments combined with the best team and industry leading premium brands and strong execution enable us to achieve record March quarter revenue.' Is now the time to buy HZO? Find out in our full research report (it's free). Revenue: $631.5 million vs analyst estimates of $582.4 million (8.3% year-on-year growth, 8.4% beat) Adjusted EPS: $0.23 vs analyst estimates of $0.19 (19.3% beat) Adjusted EBITDA: $30.92 million vs analyst estimates of $28.73 million (4.9% margin, 7.6% beat) Management lowered its full-year Adjusted EPS guidance to $1.90 at the midpoint, a 17.4% decrease EBITDA guidance for the full year is $155 million at the midpoint, below analyst estimates of $166.1 million Operating Margin: 3.6%, in line with the same quarter last year Locations: 71 at quarter end, down from 83 in the same quarter last year Same-Store Sales rose 11% year on year (2% in the same quarter last year) Market Capitalization: $545.9 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. James Hardiman (Citi): Asked about the drivers behind the 11% same-store sales growth and the expected decline in April. CFO Mike McLamb explained that growth was largely due to premium product mix, while unit volumes fell and April is expected to see further softness. Michael Swartz (Truist Securities): Inquired about direct tariff costs and margin impacts. McLamb clarified that guidance does not include significant direct tariff costs, and margin declines are attributed mainly to promotions and product mix. Joe Altobello (Raymond James): Questioned the promotional environment and industry inventory levels. CEO Brett McGill said promotions are now more about overcoming consumer uncertainty than excess inventory, and online engagement remains strong. Eric Wold (Texas Capital Securities): Pressed on demand softness across price points and the effectiveness of promotions. McGill noted softness across all segments, with premium buyers still seeking deals, and said promotions may be less effective during periods of high uncertainty. Anna Glaessgen (B. Riley Securities): Asked about cancellations and the effect of tariffs on future pricing. McGill reported no uptick in cancellations and expects any price increases related to tariffs to be phased in with new model years, not immediately. In the coming quarters, the StockStory team will watch for (1) stabilization in promotional activity and signs that margin pressure is easing, (2) continued growth and resilience in higher-margin marina and superyacht services, and (3) the impact of tariff developments on consumer demand and industry sentiment. Trends in inventory management and digital engagement will also serve as important indicators of MarineMax's ability to navigate ongoing uncertainty. MarineMax currently trades at $25.49, up from $19.24 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
5 hours ago
- Business
- Yahoo
LevelJump Announces 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce its financial results for the year ended December 31, 2024. Financial and Operational Highlights Revenues were $17.7 million in 2024 compared to $12.6 million in revenues for 2023, a year over year revenue increase of 41%. Canadian Teleradiology Services, Inc., the Company's 100% owned subsidiary had EBITDA for 2024 of $3.35 million. 2024 Financial Results for fourth quarter and year Revenues of $4.8 million in Q4 2024 and $17.7 million for the year 2024 with a net profit of $1.95 million for Q4 2024 and a net profit of $1.2 million for the year 2024. EBITDA of $395,936 for Q4 2024 and $1,545,298 for the year 2024. Subsequent Events Subsequent to the year end, the Company entered an agreement to acquire two additional diagnostic imaging outpatient clinic locations in Calgary, Alberta. The transaction is expected to close towards the end of July 2025. See the Company's news release dated June 13, 2025. Management Comments "2024 was a transformative year for our Company, marked by significant growth, particularly within our clinic operations," said Mitch Geisler, CEO. "Our year-over-year revenue increased by more than 40%, and we achieved strong EBITDA performance. We are now interpreting imaging scans for approximately 200,000 patients annually across all operations. Our focus remains on driving organic growth and advancing our long-term vision for continued expansion." Non-IFRS Financial Measures This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity. For further details on the results, please refer to LevelJump's Management, Discussion and Analysis and Consolidated Financial Statements for the year ended December 31, 2024, which are available on the Company's website ( and under the Company's profile on SEDAR+ ( About LevelJump Healthcare LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve. ON BEHALF OF THE BOARD OF DIRECTORS OFLEVELJUMP HEALTHCARE CORP. Mitchell GeislerChief Executive Officerinfo@ CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable). Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Barnama
14 hours ago
- Health
- Barnama
KPJ Healthcare Launches KWAN Mobile Clinic At HSAJB To Support Public Healthcare In Johor
GENERAL KUALA LUMPUR, June 20 (Bernama) -- KPJ Healthcare Berhad (KPJ Healthcare) has launched the operations of its Klinik Waqaf An-Nur (KWAN) Mobile Clinic at Hospital Sultanah Aminah Johor Bahru (HSAJB), Johor, to improve access to affordable care and support emergency services for the public. In a statement today, it said the mobile clinic provides after-hours treatment for non-critical cases and is aimed at reducing congestion at the hospital's Emergency and Trauma Department. The mobile clinic operates from 8 pm to 12 midnight, offering medical consultations, basic medications and medical certificates at subsidised rates equivalent to those at government hospitals and also supported by KPJ's digital Clinic Management System ('CMS'), which ensures safe, efficient and secure patient management. KPJ Healthcare President and Managing Director Chin Keat Chyuan said by expanding access to care after hours, they are helping to ease congestion at HSAJB while serving the community more effectively. 'This is also the first time a KWAN Mobile Clinic is operating within a public hospital setting in Johor, which reflects the strength of our collaboration with government partners. It is part of our commitment under the KPJ Health System to deliver more connected, inclusive care,' he said. The launch of KWAN Mobile Clinic was officiated by the Johor Menteri Besar Datuk Onn Hafiz Ghazi and attended by Johor State Executive Councillor for Health and Enviroment Ling Tian Soon, Johor State Health Department (JKNJ) Director Dr Mohtar Pungut @ Ahmad, HSAJB Director Dr Mohamad Nizam Subahir, as well as senior representatives from KPJ Healthcare and Waqaf An-Nur Corporation Berhad. The initiative is a collaboration involving the Johor State Government, JKNJ, Waqaf An-Nur Corporation Berhad, and the Johor State Health Exco Office. KWAN Mobile Clinic services in Johor began in 2017 and currently in operation through two mobile units that serve various communities across the state. The addition of HSAJB as a new service point is expected to increase outreach to patients, including those seeking treatment at public hospitals. To date, KWAN has treated more than 2.2 million patients nationwide through a network comprising eight static clinics, eight dialysis centres with 192 dialysis machines, and nine mobile units.
BBC News
a day ago
- Sport
- BBC News
Rooney gave Plymouth 'glowing reference'
New Plymouth Argyle boss Tom Cleverley says he consulted former Pilgrims head coach Wayne Rooney before taking on the pair were team-mates at Manchester United where they won the 2013 Premier League together as well as playing alongside one another for England captain Rooney left his role as Argyle boss on 31 December with the club bottom of the table to be replaced by Miron was appointed earlier this month after Muslic left to take over at German side Schalke."I spoke not just with Wayne but other people who I know that have played for or coached at the club," Cleverley told BBC Radio Devon. "He gave the club and the place a glowing reference and he's obviously someone's opinion that I can trust."I played with him for many years and I think it's important that I did some references, but most of all is what I see now through my own eyes."That will really start on Monday when I get on the pitch with the players and I make my own judgements, but I like to thoroughly research whatever I'm about to dive in to and the references were glowing." The role at Argyle is 35-year-old Cleverley's second as a head coach, having been in charge at Watford last says that experience at the Hornets - who have had 10 permanent managers since sacking Nigel Pearson in 2020 - will stand him in good stead for his future career in management."It's obviously a football club that has its challenges being the head coach," Cleverley said."I had 14 months there that have really given me some good experience to handle things throughout the rest of my career."I'm grateful for that experience and now I feel like I can really translate that into a longer term project with real stability and I think you'll see me flourish as a coach."Cleverley takes over a Pilgrims side that dropped back to the third tier after two seasons in the chairman Simon Hallett is looking for new investment, and the club was linked with a bidder that included former Wales captain Gareth Bale among their says returning to the Championship is his "number one goal", but says it is important to build a legacy at the club as well."I also want to create a long-term process that doesn't just mean we're promoted or we're winning games over a short term," he added."I want to create a process that can have real sustainability to it, and when we eventually do go up a level, it's a process that we can continue and adapt."You have to be adaptable when you have a process, it's never going to be too rigid or too stubborn."I'm someone who does like to listen and get people's opinion and adapt from there whilst having a core set of principles."
Time of India
3 days ago
- Business
- Time of India
Promoter, PE & VC selling crosses Rs 40,000 crore in 2 weeks: Red flag for Nifty bulls?
Raising eyebrows about stretched valuations and supply overhangs in a soaring market, massive selling by promoters, private equity and venture capital investors has crossed Rs 40,000 crore in June so far as they continue to dump stakes at breakneck pace. Driven by daily large block and bulk deals, the massive selling spree is set to surpass last month's Rs 43,000 crore selling total, with heavyweight transactions dominating the landscape. On Tuesday alone, Vishal Mega Mart's promoter sold a 19.6% stake to mutual funds in a Rs 10,220 crore bulk deal, while Bajaj Finserv's promoter offloaded approximately Rs 5,500 crore worth of shares earlier in the month, according to Prime Database and NSE. The selling frenzy includes some of the market's most prominent names. Walmart-owned Flipkart divested its entire 6% stake in Aditya Birla Fashion & Retail (ABFRL) through a Rs 588 crore bulk deal, while Reliance Industries' Rs 9,580 crore stake sale in Asian Paints added substantial weight to the two-week tally. Other companies witnessing promoter stake sales include Alkem Laboratories, Jubilant Foodworks, Azad Engineering, Suzlon Energy, and Kaynes Technology India. Live Events The breakdown shows promoter selling of Rs 23,820 crore, alongside PE/VC divestments worth Rs 8,500 crore in the first fortnight of June. If you add RIL's stake sale of Rs 9,580 crore, the total adds up to Rs 41,900 crore. Also Read | Rs 43,000 crore selloff by promoters! Insider exits flash warning sign for Nifty bulls Capital Migration Pattern Emerges "Where is this capital flowing? Evidence points to real estate and alternative investments like Portfolio Management Services (PMS) and Category II/III Alternative Investment Funds (AIFs)," Akshay Badjate, Fund Manager at Merisis PMS, told ET Markets. Latest SEBI data reveals Category II AIFs, including real estate and private equity funds, managing ₹13.58 lakh crore as of March 2025, up from ₹9.54 lakh crore in September 2023—a 42% surge. Category III AIFs focused on listed equities and derivatives grew 58% year-on-year to ₹2.3 trillion by March 2025. "Over the last two years (June 2023–June 2025), insider selling has coincided with ₹5.5 lakh crore in combined Category II/III AIF and PMS inflows, with real estate absorbing nearly ₹74,000 crore by December 2024," Badjate adds. Also Read | Mukesh Ambani's masterstroke: Rs 500 crore bet delivers Rs 9,000 crore windfall gain for Reliance Industries Market Resilience Despite Supply Overhang Despite the selling pressure, domestic institutional investors have provided crucial support. DIIs have been net buyers with purchases exceeding ₹49,000 crore in June, while foreign institutional investors turned net sellers, offloading nearly ₹7,000 crore worth of equities. 'While the increased supply from promoter and PE/VC selling indeed creates a supply overhang, the substantial domestic inflows, particularly from mutual funds, insurance companies, and pension funds, have, to date, cushioned the market and prevented any sharp correction. However, this rising supply could potentially cap upside potential in the near term, especially if global volatility persists or domestic flows begin to slow down,' says Mayank Jain, Market Analyst, Strategic Exits, Not Panic Selling Sunny Agrawal, DVP and Fundamental Research Analyst at SBI Securities, argues that promoter selling isn't necessarily a red flag as many PE funds are bound to return money to their investors and have limited duration for which they can remain invested. Hence, they are bound to book profit at an opportune time, he said. "Regarding promoter selling, many times they too sell the equity in the company to meet personal requirements and hence cant be a red flag always. Hence, inference can vary on case to case basis," Agrawal adds. Valuation Concerns Mount However, concerns about stretched valuations persist. "The heavy insider selling is not a definitive signal of a market peak but underscores valid concerns about current unsustainable valuations, particularly in several pockets of the small- and mid-cap segments," warns Badjate. The Nifty Midcap 150 declined 1.5% in June, reflecting selective pressure on broader market segments. "Selling by promoters/PE is being witnessed in few stocks and in those companies, in the short term, upside can be capped as most of the demand from institutions have been fulfilled," says Agrawal. "From the overall equity market perspective, cap on upside is likely to be limited, as the market has become narrow and investors are chasing select companies which have robust earnings growth outlook in the current uncertain business environment." Investment Strategy Implications At Merisis PMS, "one of the key parameters to screen viable investment opportunities is to look for Companies where promoter / insider holding remains steady in spite of strong recent price performance or is in fact on the rise, as it reflects the promoter's internal optimism around his business prospects for the foreseeable future," states Badjate. Jain observes that "large investor selling, particularly during periods of high valuations, serves as a signal that warrants caution rather than an outright red flag." 'It reflects a combination of strategic portfolio decisions and an attempt to capitalize on favorable market conditions. Investors should closely monitor whether domestic inflows continue to offset the increased supply and remain alert for any signs of weakening market fundamentals or a sharp reversal in sentiment. In this environment, it is prudent for investors to focus on companies with strong fundamentals and robust growth prospects,' he explained. As Sensex, Nifty eye fresh record highs, the key question remains whether robust domestic inflows can continue absorbing this unprecedented supply pressure. ( Disclaimer : Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times) ETMarkets WhatsApp channel )
